Erlotinib (150 mg daily)

DRUG2 trials

Sponsors

OBI Pharma, Inc, The First Affiliated Hospital with Nanjing Medical University

Conditions

AMD - Age-Related Macular DegenerationNon-small Cell Lung Cancer

Phase 1

Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

Not yet recruitingNCT07418177

The First Affiliated Hospital with Nanjing Medical UniversityAMD - Age-Related Macular Degeneration

Start: 2026-02-10End: 2028-12-31Target: 9Updated: 2026-02-18

Phase 2

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RecruitingNCT05442060

OBI Pharma, IncNon-small Cell Lung Cancer

Start: 2022-07-27End: 2026-05-31Target: 60Updated: 2025-08-03